Pneumococcal vaccines: understanding centers for disease control and prevention recommendations

Mehdi Mirsaeidi, Dean E. Schraufnagel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Streptococcus pneumoniae infection is a common and serious health problem that is best prevented by the pneumococcal vaccine. The first vaccine approved by the U.S. Federal Drug Administration in 1977 contained 14 polysaccharide antigens. An improved vaccine introduced in 1983 included 23 polysaccharide antigens. Both vaccines were effective for immunocompetent adults; however, young children and immunocompromised adults remained susceptible. A pediatric vaccine was developed consisting of the capsular antigens of seven pneumococcal serotypes commonly found in children. The antigens in this preparation are covalently conjugated to diphtheria protein to make them more antigenic. The conjugate vaccine was expanded to include 13 serotypes by 2010. Although more immunogenic, the conjugate vaccine has fewer serotypes than the older 23-valent vaccine. The U.S. Centers for Disease Control and Prevention recommend that children at risk for pneumococcal pneumonia as defined by the presence of chronic disease should receive the 13-valent conjugated vaccine. Adults at risk for pneumococcal pneumonia, which includes those over 65 years of age and those who have a chronic disease, should receive the 23-polysaccharide vaccine. Immunosuppressed patients of any age should receive both vaccines. Adults should be revaccinated once at age 65 years or older with the 23-polysaccharide vaccine provided that at least 5 years have elapsed since the previous vaccination.

Original languageEnglish (US)
Pages (from-to)980-985
Number of pages6
JournalAnnals of the American Thoracic Society
Volume11
Issue number6
DOIs
StatePublished - Jul 1 2014
Externally publishedYes

Fingerprint

Pneumococcal Vaccines
Centers for Disease Control and Prevention (U.S.)
Vaccines
Polysaccharides
Pneumococcal Pneumonia
Antigens
Conjugate Vaccines
Chronic Disease
Pneumococcal Infections
Diphtheria
Vaccination
Pediatrics
Health

Keywords

  • adults
  • PCV13
  • pneumococcal vaccine
  • PPV23
  • vaccination

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pneumococcal vaccines : understanding centers for disease control and prevention recommendations. / Mirsaeidi, Mehdi; Schraufnagel, Dean E.

In: Annals of the American Thoracic Society, Vol. 11, No. 6, 01.07.2014, p. 980-985.

Research output: Contribution to journalArticle

@article{96606c2e6fab4a60b90274c0335ebe32,
title = "Pneumococcal vaccines: understanding centers for disease control and prevention recommendations",
abstract = "Streptococcus pneumoniae infection is a common and serious health problem that is best prevented by the pneumococcal vaccine. The first vaccine approved by the U.S. Federal Drug Administration in 1977 contained 14 polysaccharide antigens. An improved vaccine introduced in 1983 included 23 polysaccharide antigens. Both vaccines were effective for immunocompetent adults; however, young children and immunocompromised adults remained susceptible. A pediatric vaccine was developed consisting of the capsular antigens of seven pneumococcal serotypes commonly found in children. The antigens in this preparation are covalently conjugated to diphtheria protein to make them more antigenic. The conjugate vaccine was expanded to include 13 serotypes by 2010. Although more immunogenic, the conjugate vaccine has fewer serotypes than the older 23-valent vaccine. The U.S. Centers for Disease Control and Prevention recommend that children at risk for pneumococcal pneumonia as defined by the presence of chronic disease should receive the 13-valent conjugated vaccine. Adults at risk for pneumococcal pneumonia, which includes those over 65 years of age and those who have a chronic disease, should receive the 23-polysaccharide vaccine. Immunosuppressed patients of any age should receive both vaccines. Adults should be revaccinated once at age 65 years or older with the 23-polysaccharide vaccine provided that at least 5 years have elapsed since the previous vaccination.",
keywords = "adults, PCV13, pneumococcal vaccine, PPV23, vaccination",
author = "Mehdi Mirsaeidi and Schraufnagel, {Dean E.}",
year = "2014",
month = "7",
day = "1",
doi = "10.1513/AnnalsATS.201401-042CME",
language = "English (US)",
volume = "11",
pages = "980--985",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Pneumococcal vaccines

T2 - understanding centers for disease control and prevention recommendations

AU - Mirsaeidi, Mehdi

AU - Schraufnagel, Dean E.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Streptococcus pneumoniae infection is a common and serious health problem that is best prevented by the pneumococcal vaccine. The first vaccine approved by the U.S. Federal Drug Administration in 1977 contained 14 polysaccharide antigens. An improved vaccine introduced in 1983 included 23 polysaccharide antigens. Both vaccines were effective for immunocompetent adults; however, young children and immunocompromised adults remained susceptible. A pediatric vaccine was developed consisting of the capsular antigens of seven pneumococcal serotypes commonly found in children. The antigens in this preparation are covalently conjugated to diphtheria protein to make them more antigenic. The conjugate vaccine was expanded to include 13 serotypes by 2010. Although more immunogenic, the conjugate vaccine has fewer serotypes than the older 23-valent vaccine. The U.S. Centers for Disease Control and Prevention recommend that children at risk for pneumococcal pneumonia as defined by the presence of chronic disease should receive the 13-valent conjugated vaccine. Adults at risk for pneumococcal pneumonia, which includes those over 65 years of age and those who have a chronic disease, should receive the 23-polysaccharide vaccine. Immunosuppressed patients of any age should receive both vaccines. Adults should be revaccinated once at age 65 years or older with the 23-polysaccharide vaccine provided that at least 5 years have elapsed since the previous vaccination.

AB - Streptococcus pneumoniae infection is a common and serious health problem that is best prevented by the pneumococcal vaccine. The first vaccine approved by the U.S. Federal Drug Administration in 1977 contained 14 polysaccharide antigens. An improved vaccine introduced in 1983 included 23 polysaccharide antigens. Both vaccines were effective for immunocompetent adults; however, young children and immunocompromised adults remained susceptible. A pediatric vaccine was developed consisting of the capsular antigens of seven pneumococcal serotypes commonly found in children. The antigens in this preparation are covalently conjugated to diphtheria protein to make them more antigenic. The conjugate vaccine was expanded to include 13 serotypes by 2010. Although more immunogenic, the conjugate vaccine has fewer serotypes than the older 23-valent vaccine. The U.S. Centers for Disease Control and Prevention recommend that children at risk for pneumococcal pneumonia as defined by the presence of chronic disease should receive the 13-valent conjugated vaccine. Adults at risk for pneumococcal pneumonia, which includes those over 65 years of age and those who have a chronic disease, should receive the 23-polysaccharide vaccine. Immunosuppressed patients of any age should receive both vaccines. Adults should be revaccinated once at age 65 years or older with the 23-polysaccharide vaccine provided that at least 5 years have elapsed since the previous vaccination.

KW - adults

KW - PCV13

KW - pneumococcal vaccine

KW - PPV23

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=84927565799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927565799&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201401-042CME

DO - 10.1513/AnnalsATS.201401-042CME

M3 - Article

C2 - 25032872

AN - SCOPUS:84908217031

VL - 11

SP - 980

EP - 985

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 6

ER -